Evidence map›Paper›PMID 33912155›Full record

ArticleFrontiers in immunology2021

Increased Pentraxin 3 Levels Correlate With IVIG Responsiveness and Coronary Artery Aneurysm Formation in Kawasaki Disease.

Toshiyuki Kitoh, Tsuyoshi Ohara, Taichiro Muto, Akihisa Okumura, Reizo Baba, Yusuke Koizumi, Yuka Yamagishi, Hiroshige Mikamo, Kenji Daigo, Takao Hamakubo

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Biomarkers in Primary Systemic Vasculitides: Narrative Review.International journal of molecular sciences · 2026
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Markers of Endothelial Dysfunction in Kawasaki Disease: An Update.Clinical reviews in allergy & immunology · 2024
    Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Toshiyuki KitohLaboratory of Pediatrics, School of Pharmacy, Aichi Gakuin University, Nagoya, Japan.
Tsuyoshi OharaLaboratory of Pediatrics, School of Pharmacy, Aichi Gakuin University, Nagoya, Japan.
Taichiro MutoDepartment of Pediatrics, School of Medicine, Aichi Medical University, Nagakute, Japan.
Akihisa OkumuraDepartment of Pediatrics, School of Medicine, Aichi Medical University, Nagakute, Japan.
Reizo BabaDepartment of Pediatrics, School of Medicine, Aichi Medical University, Nagakute, Japan.
Yusuke KoizumiDepartment of Clinical Infectious Diseases, School of Medicine, Aichi Medical University, Nagakute, Japan.
Yuka YamagishiDepartment of Clinical Infectious Diseases, School of Medicine, Aichi Medical University, Nagakute, Japan.
Hiroshige MikamoDepartment of Clinical Infectious Diseases, School of Medicine, Aichi Medical University, Nagakute, Japan.
Kenji DaigoDepartment of Protein-protein Interaction Research, Institute for Advanced Medical Sciences, Nippon Medical School, Tokyo, Japan.
Takao HamakuboDepartment of Protein-protein Interaction Research, Institute for Advanced Medical Sciences, Nippon Medical School, Tokyo, Japan.
Aichi Medical University · JPAichi Gakuin University · JPNippon Medical School · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Kawasaki disease (KD) is a febrile disease of childhood characterized by systemic vasculitis that can lead to coronary artery lesions (CAL). This was a prospective cohort study to determine the levels of the pentraxin 3 (PTX3), soluble CD24-Subtype (Presepsin) and N-terminal pro-brain natriuretic peptide (NT-pro BNP) in consecutive KD patients. From January 2013 to March 2015, all patients with KD admitted to Aichi Medical University Hospital who provided consent had their plasma saved before IVIG administration. In total, 97 cases were registered. 22 cases of incomplete KD were excluded from the outcome analysis. The total 75 cases were used for statistical analyses. A PTX3 threshold of >7.92 ng/ml provided a specificity of 88.5 %, a sensitivity of 94.4 %, and a likelihood ratio as high as 15.92 for the diagnosis of KD compared with febrile non-KD controls. Although an echocardiographic diagnosis of CAL in the early course of the disease was confirmed in 24 cases, it was not in the remaining 51 cases. Neither NT-proBNP nor Presepsin had statistical significance for the prediction of the echocardiographic CAL diagnosis. Only PTX3 was significantly predictive of the echocardiographic CAL diagnosis (p=0.01). The PTX3 level was significantly higher in the intravenous immunoglobulin (IVIG) non-responders (45.9±7.45) than in the IVIG responders (17.0 ± 1.46 ng/ml) (p< 0.001). The PTX3 level also correlated with the number of IVIG treatment courses needed to resolve fever (R² =0.64). Persistent CAL (pCAL) formation was observed in three cases; one of aneurysm only and two aneurysms with dilatations. The patients with pCAL had significantly higher PTX3 levels (85 ± 8.4 ng/ml) than patients without pCAL (22 ± 2.2 ng/ml) (p< 0.0001). In terms of pCAL prediction, the area under the curve (AUC) of receiver operating characteristic ROC curve of PTX3 was 0.99, and it was significantly greater than that of Presepsin (0.67) or NT-proBNP (0.75). PTX3 is a soluble pattern recognition molecule that acts as a main component of the innate immune system. These data suggest that PTX3 can be utilized as a definitive biomarker for the prediction of IVIG resistance and subsequent CAL formation in patients with KD.

Indexed as

BiomarkersCase-Control StudiesChildChild, PreschoolCoronary AneurysmC-Reactive ProteinEchocardiographyFemaleHumansImmunoglobulins, IntravenousInfantLipopolysaccharide ReceptorsMaleMucocutaneous Lymph Node SyndromeNatriuretic Peptide, BrainPentraxinsBiomarkersC-Reactive ProteinImmunoglobulins, IntravenousLipopolysaccharide ReceptorsNatriuretic Peptide, BrainPentraxinsPeptide Fragmentspresepsin protein, humanpro-brain natriuretic peptide (1-76)Serum Amyloid P-Componentcoronary aneurysmcoronary artery abnormalitiesintravenous immunoglobulin therapyKawasaki diseaseN-terminal pro-brain natriuretic peptidepentraxin 3presepsinsystemic vasculitis

Identifiers

PMID33912155
PMCPMC8072470
OpenAlexW3157019253

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.